Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs

Canadian Veterinary Journal

Volumn 54, Issue 3, 2013, Pages 255-261

  Arita, Shinji ^a,b   Arita, Noboru ^b   Hikasa, Yoshiaki ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b Arita Sougo Animal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DOSE RESPONSE; FEMALE; HEART FAILURE; MALE; PILOT STUDY; PULMONARY HYPERTENSION;

ANIMALS; BENZAMIDES; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE; HYPERTENSION, PULMONARY; MALE; PILOT PROJECTS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84875002927     PISSN: 00085286     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Steele JL, Henik RA. Pulmonary hypertention. In: King LG, ed. Textbook of Respiratory Disease in Dogs and Cats. St. Louis, Missouri: Saunders, 2004:498-504.
2. Cooper R, Ghali J, Simmons BE, Castaner A. Elevated pulmonary artery pressure. An independent predictor of mortality. Chest 1991; 99:112-120.
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
4. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182:1171-1177.
5. Johnson L, Boon J, Orton EC. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. J Vet Intern Med 1999;13:440-447.
6. Bach JF, Rozanski EA, MacGregor J, Betkowski JM, Rush JE. Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs. J Vet Intern Med 2006;20:1132-1135.
7. Chetboul V, Serres F, Tissier R, et al. Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease. J Vet Intern Med 2009;23:984-994.
8. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertention Registry. Circulation 1989;80:1198-1206.
9. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX. Cellular and molecular mechanisms of pulmonary vascular remodeling: Role in the development of pulmonary hypertension. Microvasc Res 2004;68:75-103.
10. Barst RJ. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 2005;115:2691-2694.
11. Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:81-88.
12. Ogawa A, Nakamura K, Matsubara H, et al. Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Circulation 2005; 112:1806-1812.
13. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295: 139-145.
14. Isotani M, Ishida N, Tominaga M, et al. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. J Vet Intern Med 2008;22:985-988.
15. London CA. Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med 2009;24:106-112.
16. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008; 118:2372-2379.
17. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
18. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-1413.
19. Abe K, Toba M, Alzoubi A, et al. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Cell Mol Biol 2011 ; 45:804-808.
20. Brown AJ, Davison E, Sleeper MM. Clinical efficacy of sildenafil in treatment of pulmonary arterial hypertension in dogs. J Vet Intern Med 2010;24:850-854.
21. Hori Y, Yamano S, Kanai K, Hoshi F, Itoh N, Higuchi S. Clinical implications of measurement of plasma atrial natriuretic peptide concentration in dogs with spontaneous heart disease. J Am Vet Med Assoc 2011;239:1077-1083.
22. Sahn DJ, DeMaria A, Kisslo J, Weyman, A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083.
23. Otsuji Y, Kisanuki A, Toyonaga K, et al. Right ventricular stiffness measured by a new method without volume estimation in coronary artery disease. Am J Cardiol 1996;78:298-303.
24. Tei C. New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 1995;26:135-136.
25. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777-802.
26. Uematsu M, Miyatake K, Tanaka N, et al. Myocardial velocity gradient as a new indicator of regional left ventricular contraction: Detection by a two-dimensional tissue Doppler imaging technique. J Am Coll Cardiol 1995;26:217-223.
27. Hatano M, Yao A, Shiga T, Kinugawa K, Hirata Y, Nagai R. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J 2010;51:272-276.
28. Vuorinen K, Gao F, Oury TD, Kinnula VL, Myllârniemi M. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res 2007;33:357-373.
29. Atkinson KJ, Fine DM, Thombs LA, Gorelick JJ, Durham HE. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. J Vet Intern Med 2009;23:1190-1196.
30. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006;61:736.
31. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006;173:769-776.
32. Gouni V, Serres FJ, Pouchelon JL, et al. Quantification of mitral valve regurgitation in dogs with degenerative mitral valve disease by use of the proximal isovelocity surface area method. J Am Vet Med Assoc 2007; 231:399-406.
33. Klein M, Schermuly RT, Ellinghaus P, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008;118:2081-2090.
34. Moonarmart W, Boswood A, Luis Fuentes V, Brodbelt D, Souttar K, Elliott J. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract 2010;51:84-96.
35. Borgarelli M, Savarino P, Crosara S, et al. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med 2008;22:120-128.
36. Greco DS, Biller B, Van Liew CH. Measurement of plasma atrial natriuretic peptide as an indicator of prognosis in dogs with cardiac disease. Can Vet J 2003;44:293-297.
37. Serres F, Pouchelon JL, Poujol L, et al. Plasma N-terminal pro-B-type natriuretic peptide concentration helps to predict survival in dogs with symptomatic degenerative mitral valve disease regardless of and in combination with the initial clinical status at admission. J Vet Cardiol 2009;11:103-121.
38. Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994;23:570-578.